Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Company Announcements

Bolt Biotherapeutics Announces Board Reshuffle and New Appointment

Bolt Biotherapeutics (BOLT) just unveiled an update.

Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Frank D. Lee, effective September 3, 2024; both resignations are amicable without any conflicts. Filling the vacancy, Jakob Dupont, with a robust background in biopharmaceuticals and multiple drug approvals to his credit, joins the board. His term as a Class II member will conclude at the 2026 annual stockholders’ meeting, and he will receive the standard compensation for his role as a non-employee director. Dupont has no undisclosed transactions that could pose conflicts of interest.

Learn more about BOLT stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBolt Biotherapeutics presents updated preclinical data for BDC-4182
TheFlyBolt Biotherapeutics names Brian O’Callaghan chairman
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App